A patient with exertional dyspnea, hypertension, and an ejection fraction (EF) of 60% fits a familiar HFpEF risk profile. But those facts do not establish HFpEF—and the EF does not rule it out. The primary-care task is to decide whether symptoms reflect a heart-failure syndrome with elevated filling pressures, or whether the risk profile sits beside another cause of breathlessness.
This is the diagnostic boundary worth mastering: how to move from a preserved EF and compatible demographics to adequate clinical evidence, and what to do when resting tests do not settle the question.
EF answers a narrower question than dyspnea does
Ejection fraction is the proportion of blood in the left ventricle at the end of filling that is expelled with each contraction. It describes a part of systolic pump function. It does not measure how easily the ventricle relaxes, how much pressure is needed to fill it, or how it responds to exercise.
A stiff ventricle may fill only at higher pressure. During activity, the heart must accommodate increased blood flow; if filling pressures rise, that pressure can be transmitted backward toward the left atrium and lungs, producing exertional breathlessness even when EF is preserved. Resting symptoms, examination, or measurements may be less revealing when the problem appears mainly with exertion.
In the conventional EF-based classification, HFpEF refers to heart failure with an EF generally at or above 50%. The EF classifies the heart-failure phenotype; it does not diagnose the syndrome. U.S. heart-failure guidance calls for evidence of increased left-ventricular filling pressures at rest or with provocation to support HFpEF. The current multisociety definition also emphasizes the combined clinical picture rather than a single stand-alone test.
Risk clues raise suspicion; they are not diagnostic criteria
Long-standing hypertension can contribute to ventricular remodeling and impaired relaxation. Older age, female sex, obesity, diabetes, and atrial fibrillation are also useful clues when considering HFpEF. They shift clinical suspicion; none is a required criterion, and none proves that a particular patient’s dyspnea is caused by heart failure.
| Finding | What it contributes | What it does not establish |
|---|---|---|
| Hypertension, older age, female sex, obesity, diabetes, or atrial fibrillation | Raises or shapes the prior suspicion for HFpEF | A heart-failure diagnosis or elevated filling pressure in this patient |
| EF at or above 50% | Identifies a preserved-EF phenotype if heart failure is present | Normal filling, normal relaxation, or absence of heart failure |
| LV hypertrophy, left-atrial enlargement, or abnormal diastolic indices on echo | Supports structural or functional cardiac change | HFpEF by itself; individual findings need clinical context |
| Elevated natriuretic peptide or imaging evidence of congestion | Adds objective support to the clinical assessment | A cause of symptoms without considering other conditions |
The distinction matters in family medicine, where risk factors are common and breathlessness often has more than one contributor. A person can have hypertension and an abnormal relaxation pattern without a symptomatic heart-failure syndrome. Conversely, a normal-looking resting assessment does not always end the evaluation when exertional symptoms remain concerning.
Build the decision from the patient’s baseline
Start by reconstructing what has changed. Ask when breathlessness began, whether it is progressing, and what the patient could do before compared with now: walk a usual distance, climb stairs, do housework, or work a shift. Clarify orthopnea, waking breathless at night, swelling, and weight changes. Prior heart-failure episodes, usual function, medicines, and kidney disease can help put current findings in context.
Then keep competing explanations in view. Ask about cough, wheeze, smoking and lung disease; palpitations or episodic symptoms; chest discomfort or known coronary disease; anemia-related symptoms; and activity changes or deconditioning. Obesity, kidney disease, valve disease, and pulmonary conditions may complicate the picture or mimic part of it. Do not fill gaps in the history with assumptions.
Look beyond the EF on the resting tests
When HF is suspected, examination and initial testing should be interpreted together. Look for findings that support congestion, such as elevated jugular venous pressure, crackles, edema, or a meaningful weight trend, while recognizing that no single finding settles the diagnosis. Depending on the presentation, an ECG, chest imaging, natriuretic peptide testing, and echocardiography can help distinguish cardiac from noncardiac causes.
On the echocardiogram, read more than the EF: consider ventricular structure, left-atrial size, diastolic measurements, valve disease, and right-heart findings. These findings can support the formulation, but an isolated abnormal measurement is not a substitute for linking the test to the symptoms and clinical course.
BNP or NT-proBNP can provide useful support, but a normal value does not reliably exclude HFpEF in every patient. Levels may be lower in people with obesity, including some with HFpEF; kidney dysfunction may raise them. Interpret results in the context of the patient, the assay, and the other findings rather than treating one result as a verdict.
When the resting evaluation and symptoms disagree
If symptoms persist but the resting evaluation is equivocal, do not jump from “normal EF” to “not cardiac”—or from several risk factors to “definitely HFpEF.” Diagnostic scores such as H₂FPEF or HFA-PEFF can organize the evidence and estimate probability. They are aids to reasoning, not independent proof.
For symptoms that occur mainly with exertion, a specialist may consider exercise echocardiography or invasive hemodynamic testing to assess whether filling pressures rise abnormally with activity. In primary care, the practical decision is whether the available findings adequately support the diagnosis and plan, or whether persistent functional limitation and unresolved uncertainty warrant further evaluation or referral.
Two common shortcuts deserve particular caution: calling LV hypertrophy or impaired relaxation “HFpEF” without establishing a heart-failure syndrome, and using improvement after a diuretic as proof of the diagnosis. Treatment response may inform the overall picture, but it does not replace diagnostic reasoning. New or severe breathlessness at rest, hypoxemia, chest pain, or hemodynamic instability calls for urgent assessment rather than a slow outpatient workup.
Practical takeaways
- EF measures the fraction ejected, not the pressure required to fill the ventricle.
- Hypertension, older age, and female sex are probability clues—not diagnostic criteria.
- Assess baseline function and symptom trajectory, then connect symptoms to objective cardiac evidence.
- A normal natriuretic peptide or resting test does not always close the question, particularly when obesity or exertional-only symptoms complicate interpretation.
- Use scores to structure uncertainty; consider specialist evaluation when the diagnosis remains unresolved and symptoms persist.
